去年，Jazz Pharmaceuticals PLC表现最佳的业务板块Xywav实现营收1.66B美元。United States的营收贡献最高，去年达到3.83B美元。最近一个季度，截至2026-06-30，Jazz Pharmaceuticals PLC表现最佳的业务板块Xywav实现营收471.20M美元。United States的营收贡献最高，达到1.08B美元。

业务

营业收入

占比

年报

年报

单季报

Xywav

Epidiolex/epidyolex

Rylaze

Zepzelca

High-sodium oxybate AG royalty revenue

Defitelio/defibrotide

Vyxeos

Xyrem

Modeyso

Royalties and contract revenues

Ziihera

sativex

Other Revenue

Oxybate

Sunosi

Erwianaze/Erwinase

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

Xywav

1.66B(38.83%)

1.47B(36.21%)

1.27B(33.20%)

--(--)

Epidiolex/epidyolex

1.06B(24.82%)

972.42M(23.90%)

845.47M(22.05%)

--(--)

Rylaze

402.92M(9.44%)

410.85M(10.10%)

394.23M(10.28%)

281.66M(7.70%)

85.63M(2.77%)

--(--)

Zepzelca

307.31M(7.20%)

320.32M(7.87%)

289.53M(7.55%)

269.91M(7.38%)

246.81M(7.98%)

90.38M(3.82%)

--(--)

High-sodium oxybate AG royalty revenue

211.72M(4.96%)

217.57M(5.35%)

75.92M(1.98%)

--(--)

Defitelio/defibrotide

199.39M(4.67%)

216.56M(5.32%)

184.00M(4.80%)

194.29M(5.31%)

197.93M(6.40%)

195.84M(8.29%)

172.94M(8.00%)

Vyxeos

146.71M(3.44%)

162.59M(4.00%)

147.50M(3.85%)

127.98M(3.50%)

134.06M(4.33%)

121.11M(5.12%)

121.41M(5.62%)

Xyrem

146.03M(3.42%)

233.82M(5.75%)

569.73M(14.86%)

--(--)

Modeyso

48.04M(1.13%)

--(--)

Royalties and contract revenues

34.01M(0.80%)

30.21M(0.74%)

21.34M(0.56%)

17.95M(0.49%)

15.24M(0.49%)

16.91M(0.72%)

26.16M(1.21%)

Ziihera

24.81M(0.58%)

1.05M(0.03%)

--(--)

sativex

16.28M(0.38%)

18.88M(0.46%)

19.67M(0.51%)

--(--)

Other Revenue

14.17M(0.33%)

11.47M(0.28%)

13.85M(0.36%)

6.64M(0.18%)

9.80M(0.32%)

6.84M(0.29%)

17.55M(0.81%)

Oxybate

--(--)

1.98B(54.08%)

--(--)

1.76B(74.34%)

1.64B(75.98%)

Sunosi

--(--)

782.07M(21.37%)

2.34B(75.48%)

28.33M(1.20%)

3.71M(0.17%)

Erwianaze/Erwinase

--(--)

69.38M(2.24%)

147.14M(6.23%)

177.47M(8.21%)

地区

营业收入

占比

年报

年报

单季报

United States

Europe

All Others

All Other

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

United States

3.83B(89.78%)

3.66B(89.95%)

3.49B(91.02%)

3.37B(92.10%)

2.82B(91.14%)

2.14B(89.08%)

1.97B(89.01%)

Europe

341.12M(7.99%)

312.71M(7.69%)

269.24M(7.02%)

239.64M(6.55%)

230.16M(7.44%)

175.21M(7.28%)

150.20M(6.80%)

All Others

94.87M(2.22%)

96.14M(2.36%)

74.98M(1.96%)

49.36M(1.35%)

43.84M(1.42%)

43.82M(1.82%)

46.24M(2.09%)

All Other

--(--)

43.82M(1.82%)

46.24M(2.09%)